Thank you Steve and now I am going to update on our programs. I will start with obesity and diabetes, melanocortin-4 receptor program which is partnered with AstraZeneca. This program under the direction of AstraZeneca continues to make substantial progress. In 2011, Astra designated lead compound AZD2820 which was developed by Palatin as a candidate for clinical development.